Request Demo
AB2 Bio and Nippon Shinyaku enter Tadekinig alfa licensing deal
License out/inDrug ApprovalOligonucleotide
Tadekinig alfa is designed to bind and block IL-18. Credit: TheCorgi/Shutterstock.
Tadekinig alfade an option and licencing agreIL-18 with Nippon Shinyaku, granting the latter the option to obtain exclusive rights to commercialise Tadekinig alfa in the US.
AB2 Bioerapy treats a rare paediatric condition, primaryNippon Shinyakurleukin-18 (IL-18)-driven hyperinflammatory syndrome, which can lead to rapidTadekinig alfan failure and mortality if not treated.
AB2 Bio will receive up to $36m in early payments, including a $6m interleukin-18 (IL-18)-drivenmultiple organ failure
AB2 Biopany could also receive up to $150m in development milestone payments and commercial milestone and royalty payments potentially amounting to $500m.
AB2 Bio is set to continue its preparations for a US biologics licence application (BLA) approval for the therapy for this indication.
AB2 Bioppon Shinyaku exercising its option rights and following AB2 Bio’s receipt of the BLA approval in the US, NS Pharma, Nippon Shinyaku’s wholly owned subsidiary, will undertake the marketing of the therapy.
NippoNippon Shinyaku have exclusive rights to commercialise TadeAB2 Biolfa for its primary indication in individuNS PharmaNLNippon Shinyakud X-linked inhibitor of apoptosis protein (XIAP) deficiency within the US.
Nippon Shinyaku the rights to the therapy for all other indiTadekinig alfa the country, including the US Virgin Islands, GNLRC4nd Puerto RicoX-linked inhibitor of apoptosis protein (XIAP)s of the world.
AB2 Bio CEO Djordje Filipovic stated: “This partnership will accelerate bringing Tadekinig alfa to young patients suffering from this rare and devastating disease and potentially provide a significant improvement in treatment.”
AB2 Bioig alfa is a recombinant human IL-18 binding protein.Tadekinig alfa
Tadekinig alfa MiNA Therapeutics entered a research partnership and licensing agreement with Nippon Shinyaku. The collaboration is focused on developing small activating RNA therapeutics for rare neurodegenerative conditions.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!